Central actions of valproic acid in man and in experimental models of epilepsy.
D000612:4-Aminobutyrate Transaminase / Q000037:antagonists & inhibitors; D000200:Action Potentials; D000429:Alcohol Oxidoreductases / Q000037:antagonists & inhibitors; D000445:Aldehyde Oxidoreductases / Q000037:antagonists & inhibitors; D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D004558:Electric Stimulation; D004594:Electrophysiology; D004828:Epilepsies, Partial / Q000503:physiopathology; D005998:Glycine / Q000378:metabolism; D006801:Humans; D009422:Nervous System Diseases / Q000188:drug therapy; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology*; D012701:Serotonin / Q000378:metabolism; D050644:Succinate-Semialdehyde Dehydrogenase; D013386:Succinates / Q000037:antagonists & inhibitors; D014635:Valproic Acid / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D013386:Succinates; D001224:Aspartic Acid; D012701:Serotonin; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D000429:Alcohol Oxidoreductases; C019642:alcohol dehydrogenase (NADP+); D000445:Aldehyde Oxidoreductases; C493643:ALDH5A1 protein, human; D050644:Succinate-Semialdehyde Dehydrogenase; D000612:4-Aminobutyrate Transaminase; D006152:Cyclic GMP; D005998:Glycine